Related Experiment Videos
[Occurrence of thromboembolic complications in patients with dilated cardiomyopathy. Retrospective-prospective study]
Insights
Thromboembolic events are rare in dilated cardiomyopathy (DC) patients but occur more frequently than in those with ischemic cardiomyopathy without cardiomegaly. Anticoagulant therapy may benefit these patients, irrespective of their heart rhythm.
Area of Science:
- Cardiology
- Internal Medicine
- Vascular Medicine
Context:
- Dilated cardiomyopathy (DC) presents challenges in managing thromboembolic risk.
- Understanding the prevalence of thromboembolic events in DC patients is crucial for effective treatment strategies.
Purpose:
- To determine the prevalence of thromboembolic events in patients with primary and secondary (ischemic) dilated cardiomyopathy (DC).
- To compare the incidence of thromboembolic events between DC patients and controls with heart failure but no DC.
- To assess the impact of basic rhythm (sinus rhythm vs. atrial fibrillation) on thromboembolic events in DC patients.
Summary:
- A retrospective and prospective study analyzed 126 patients with DC and compared them to controls.
- Thromboembolic events were significantly higher in DC patients (12.6%) compared to controls (1.3%).
- Incidence of thrombi and embolisms was low, with no significant difference between sinus rhythm and atrial fibrillation subgroups in DC patients.
Impact:
- The study suggests that anticoagulant therapy could be beneficial for DC patients, regardless of their underlying heart rhythm.
- Findings highlight the increased thromboembolic risk in DC patients, necessitating further investigation in prospective, multicentric trials.
- This research contributes to optimizing anticoagulation strategies for heart failure patients with dilated cardiomyopathy.
Abstract:
The purpose of the present study was to determine the prevalence of thromboembolic events in patients with primary and secondary (ischemic) dilated cardiomyopathy (DC), with regard to basic rhythm, sinus or atrial fibrillation. Retrospectively, over three years, from January 1, 1989 to December 31, 1991, the case histories of 75 inpatients with DC, mean age 56.2 +/- 14.1 years, 41 in sinus rhythm and 34 in atrial fibrillation from Clinic Hospital Split were analyzed and compared to those of 75 controls (heart failure with no DC). The incidence of thrombi, embolisms and mortality in both subgroups was similar, while the prevalence of thromboembolic events was significantly higher in the analyzed than in the control group (decompensated patients with ischemic cardiomyopathy and without cardiomegaly) (9/75:1/75, p < 0.05). Prospectively, between 9 and 22 months, from December 1, 1991 to September 30, 1993 51 consecutive decompensated outpatients with DC, in NYHA class II and III, mean age 54.2 +/- 15 years, were followed-up. Bilirubin, lactic dehydrogenase, prothrombin time and activated partial thromboplastin time were determined. 1-D and 2-D transthoracic echocardiographic exam was performed and clinical status was assessed. There were 24 patients in sinus rhythm and 27 patients in atrial fibrillation. The prevalence of thromboembolic events, thrombi and mortality in both subgroups was similar. The laboratory findings, indicators of possible thrombogenesis or thrombolysis, did not show any significant difference in both subgroups. The incidence of thrombi in both parts of this study was low, amounted to only 9.5% (12/126) with no clear signs of thromboembolism (these patients were anticoagulated!). Altogether 12.6% (16/126) patients suffered thromboembolic events, 9 in retrospective and 7 in prospective part of the trial (more patients were anticoagulated in prospective then in retrospective study, 5 versus 19; p < 0.05). We conclude that thromboembolism in patients with decompensated DC are rare, but appear at significantly higher rate than in decompensated patients with ischemic cardiomyopathy and no cardiomegaly. The beneficial effects of anticoagulant therapy are to be expected in these patients regardless of the basal rhythm. This hypothesis must, however, be assessed in a prospective, multicentric trial.